** Shares of drugmaker Vanda Pharmaceuticals fall 10.9% to $4.41 premarket
** Co says U.S. FDA declined to approve its stomach paralysis drug, tradipitant
** Co says the FDA suggested that Vanda conduct additional studies
** Will continue to pursue approval for the drug to treat gastroparesis, characterized by delayed gastric emptying
** Plans to submit separate marketing application for tradipitant to prevent vomiting during motion sickness later this year
** Stock up 17.3% YTD vs 11.3% rise in the Nasdaq Biotechnology Index
(Reporting by Sneha S K)
((Sneha.SK@thomsonreuters.com;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。